ArticleBlood cancer journal2022

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.

Diana Al-Sarayfi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.